Åke Berglund

5.3k total citations · 2 hit papers
53 papers, 2.6k citations indexed

About

Åke Berglund is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Åke Berglund has authored 53 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 17 papers in Surgery and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Åke Berglund's work include Colorectal Cancer Treatments and Studies (27 papers), Cancer Treatment and Pharmacology (13 papers) and Colorectal Cancer Surgical Treatments (11 papers). Åke Berglund is often cited by papers focused on Colorectal Cancer Treatments and Studies (27 papers), Cancer Treatment and Pharmacology (13 papers) and Colorectal Cancer Surgical Treatments (11 papers). Åke Berglund collaborates with scholars based in Sweden, Denmark and Norway. Åke Berglund's co-authors include Bengt Glimelius, Per Byström, Lars Påhlman, Peter Nygren, Calin Radu, Morten Brændengen, Kjell M. Tveit, Rolf Larsson, Hemming Johansson and Krzysztof Bujko and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and The Lancet Oncology.

In The Last Decade

Åke Berglund

52 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial

2017 395 citations Åke Berglund, Calin Radu et al. profile →
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

2023 149 citations Per J. Nilsson, Åke Berglund et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Åke Berglund Sweden	26	2.0k	1.2k	530	285	276	53	2.6k
Luigi Manzione Italy	29	2.4k 1.2×	637 0.5×	1.3k 2.4×	267 0.9×	386 1.4×	88	3.4k
Lydia G. van der Geest Netherlands	34	2.2k 1.1×	1.2k 1.0×	967 1.8×	235 0.8×	155 0.6×	93	3.1k
Thomas A. Abrams United States	25	1.4k 0.7×	655 0.5×	668 1.3×	367 1.3×	698 2.5×	84	2.4k
Roger Faroux France	23	1.7k 0.9×	599 0.5×	684 1.3×	249 0.9×	311 1.1×	98	2.5k
Jean François Seitz France	18	2.8k 1.4×	842 0.7×	1.0k 2.0×	974 3.4×	418 1.5×	37	3.7k
Kjell M. Tveit Norway	30	1.6k 0.8×	1.2k 1.0×	526 1.0×	260 0.9×	642 2.3×	79	2.8k
Eran Sadot Israel	25	1.8k 0.9×	1.2k 1.0×	833 1.6×	158 0.6×	179 0.6×	70	2.8k
Sylvain Manfrédi France	28	2.3k 1.1×	1.3k 1.1×	1.2k 2.3×	543 1.9×	343 1.2×	117	3.5k
Benoist Chibaudel France	28	2.9k 1.4×	1.0k 0.9×	1.3k 2.4×	485 1.7×	350 1.3×	157	3.7k
Pierre-Luc Etienne France	23	2.3k 1.1×	1.7k 1.4×	1.4k 2.7×	209 0.7×	118 0.4×	72	3.2k

Countries citing papers authored by Åke Berglund

Since Specialization

Citations

This map shows the geographic impact of Åke Berglund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Åke Berglund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Åke Berglund more than expected).

Fields of papers citing papers by Åke Berglund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Åke Berglund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Åke Berglund. The network helps show where Åke Berglund may publish in the future.

Co-authorship network of co-authors of Åke Berglund

This figure shows the co-authorship network connecting the top 25 collaborators of Åke Berglund. A scholar is included among the top collaborators of Åke Berglund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Åke Berglund. Åke Berglund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Glimelius, Bengt, Tanweera Khan, Eva Angenete, et al.. (2024). Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US). EClinicalMedicine. 75. 102771–102771. 7 indexed citations

Liposits, Gábor, Halla Skúladóttir, Jesper Ryg, et al.. (2022). The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study. Journal of Clinical Medicine. 11(19). 5603–5603. 11 indexed citations

Liposits, Gábor, Jesper Ryg, Halla Skúladóttir, et al.. (2022). Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy – The randomized NORDIC9-study. Journal of Geriatric Oncology. 14(1). 101408–101408. 7 indexed citations

Berglund, Åke, Marianne G. Guren, Eva Hofsli, et al.. (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. Cancer Treatment and Research Communications. 31. 100517–100517. 2 indexed citations

Hagman, Helga, Jan‐Erik Frödin, Åke Berglund, et al.. (2015). A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Annals of Oncology. 27(1). 140–147. 45 indexed citations

Malin, Marshall, et al.. (2013). Daily walking during adjuvant chemotherapy for patients with breast and colorectal cancer - a randomized pilot study. European Journal of Cancer. 49. 2 indexed citations

Byström, Per, Åke Berglund, Peter Nygren, et al.. (2012). Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncologica. 51(7). 849–859. 35 indexed citations

Qvortrup, Camilla, Ib Jarle Christensen, Bengt Glimelius, et al.. (2010). Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. Annals of Oncology. 22(2). 369–375. 19 indexed citations

Glimelius, Bengt, Hans Garmo, Åke Berglund, et al.. (2010). Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 11(1). 61–71. 107 indexed citations

10.

Johnsson, Anders, Eva Fernebro, Petra Flygare, et al.. (2010). Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer. 13(3). 155–161. 25 indexed citations

11.

Glimelius, Bengt, Michael Lahn, Ann Cleverly, et al.. (2009). A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Annals of Oncology. 21(5). 1020–1026. 22 indexed citations

12.

Berglund, Åke, et al.. (2009). Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemotherapy and Pharmacology. 65(6). 1165–1172. 140 indexed citations

13.

Glimelius, Bengt, Halfdan Sørbye, Lise Balteskard, et al.. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology. 19(5). 909–914. 36 indexed citations

14.

Radu, Calin, Åke Berglund, Lars Påhlman, & Bengt Glimelius. (2008). Short-course preoperative radiotherapy with delayed surgery in rectal cancer – A retrospective study. Radiotherapy and Oncology. 87(3). 343–349. 151 indexed citations

15.

Byström, Per, Jan‐Erik Frödin, Åke Berglund, Nils Wilking, & Bengt Glimelius. (2004). Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer. Radiotherapy and Oncology. 70(2). 171–175. 2 indexed citations

16.

Jakobsen, Anders, Åke Berglund, Bengt Glimelius, et al.. (2002). Dose-effect Relationship of Bolus 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer. Acta Oncologica. 41(6). 525–531. 23 indexed citations

17.

Berglund, Åke, Daniel Molin, Anders Larsson, R. Einarsson, & Bengt Glimelius. (2002). Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Annals of Oncology. 13(9). 1430–1437. 33 indexed citations

18.

Berglund, Åke, Bengt Glimelius, Jonas Bergh, et al.. (2002). Selection of Chemotherapy by Ex Vivo Assessment of Tumor Sensitivity to Cytotoxic Drugs: Results of a Clinical Trial. Medical Oncology. 19(3). 151–160. 8 indexed citations

19.

Berglund, Åke, Gunilla Enblad, Kristina Carlson, Bengt Glimelius, & Hans Hagberg. (2000). Long‐term follow‐up of autologous stem‐cell transplantation for follicular and transformed follicular lymphoma. European Journal Of Haematology. 65(1). 17–22. 29 indexed citations

20.

Glimelius, Bengt, Anders Jakobsen, W. Graf, et al.. (1998). Bolus injection (2–4min) versus short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. European Journal of Cancer. 34(5). 674–678. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact